Endocrine Response to a Single Injection of Goserelin 3.6 mg or Leuprolide 3.75 mg in Men with Prostate Cancer

@article{Tanaka2007EndocrineRT,
  title={Endocrine Response to a Single Injection of Goserelin 3.6 mg or Leuprolide 3.75 mg in Men with Prostate Cancer},
  author={N. Tanaka and Katsuhiko Fujimoto and Y. Hirao and K. Shimizu and S. Tsujimoto and S. Samma},
  journal={Archives of Andrology},
  year={2007},
  volume={53},
  pages={87 - 90}
}
  • N. Tanaka, Katsuhiko Fujimoto, +3 authors S. Samma
  • Published 2007
  • Biology, Medicine
  • Archives of Andrology
  • Hormonal responses were assessed in men with prostate cancer (T2-4, Nx, Mx) who were randomized to receive either a single injection of goserelin 3.6 mg or leuprolide 3.75 mg. Testosterone increased over the first week, with a significantly higher mean rate of change of total testosterone (day 3) and free testosterone (days 3 and 7) with leuprolide. Following the initial rise in luteinizing hormone (LH), the rate of decrease in LH levels was significantly greater with goserelin by day 28. There… CONTINUE READING
    10 Citations

    Topics from this paper.

    Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question.
    • L. Reis
    • Medicine
    • Endocrine-related cancer
    • 2012
    • 12
    • PDF
    ICINE IN THE USE OF LHRH
    • 2011

    References

    SHOWING 1-10 OF 17 REFERENCES
    A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    • 1,355
    Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
    • Medicine
    • The New England journal of medicine
    • 1984
    • 185
    A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
    • 31
    Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
    • 61
    • PDF